Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Colorectal Neoplasms 233Carcinoma, Non-Small-Cell Lung 132Breast Neoplasms 121Glioblastoma 88Ovarian Neoplasms 86Carcinoma, Hepatocellular 69Rectal Neoplasms 64Brain Neoplasms 57Lung Neoplasms 55Neoplasm Metastasis 54Neoplasms 52Colonic Neoplasms 50Fallopian Tube Neoplasms 43Glioma 40Carcinoma, Renal Cell 35Gliosarcoma 34Melanoma 26Adenocarcinoma of Lung 26Pancreatic Neoplasms 23Liver Neoplasms 23Uterine Cervical Neoplasms 21Stomach Neoplasms 21Recurrence 21Triple Negative Breast Neoplasms 18Kidney Neoplasms 16Endometrial Neoplasms 16Esophageal Neoplasms 15Astrocytoma 14Carcinoma, Ovarian Epithelial 13Adenocarcinoma, Bronchiolo-Alveolar 13

Interventions

Radiotherapy 2TP protocol 1Paclitaxel 1Erlotinib Hydrochloride 1Cisplatin 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasm Recurrence, Local × Bevacizumab × Clear all
NCT00095225 2008-01-29

A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)

Genentech, Inc.

Phase 2 Completed
122 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Recurrence, Local, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡